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Summary
Objectives: To report on the process and criteria for selecting acquisition protocols to include in the osteoarthritis initiative (OAI) magnetic
resonance imaging (MRI) study protocol for the knee.
Methods: Candidate knee MR acquisition protocols identiﬁed from the literature were ﬁrst optimized at 3 Tesla (T). Twelve knees from 10 sub-
jects were scanned one time with each of 16 acquisitions considered most likely to achieve the study goals and having the best optimization
results. The resultant images and multi-planar reformats were evaluated for artifacts and structural discrimination of articular cartilage at the
cartilageeﬂuid, cartilageefat, cartilageecapsule, cartilageemeniscus and cartilageecartilage interfaces.
Results: The ﬁve acquisitions comprising the ﬁnal OAI MRI protocol were assembled based on the study goals for the imaging protocol, the
image evaluation results and the need to image both knees within a 75 min time slot, including positioning. For quantitative cartilage morphom-
etry, fat-suppressed, 3D dual-echo in steady state (DESS) acquisitions appear to provide the best universal cartilage discrimination.
Conclusions: The OAI knee MRI protocol provides imaging data on multiple articular structures and features relevant to knee OA that will sup-
port a broad range of existing and anticipated measurement methods while balancing requirements for high image quality and consistency
against the practical considerations of a large multi-center cohort study. Strengths of the ﬁnal knee MRI protocol include cartilage quantiﬁca-
tion capabilities in three planes due to multi-planar reconstruction of a thin slice, high spatial resolution 3D DESS acquisition and the multiple,
non-fat-suppressed image contrasts measured during the T2 relaxation time mapping acquisition.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: COR coronal, CNR contrast-to-noise ratio, DESS dual-echo steady state, ETL echo-train length, FDA food and drug adminis-
tration, FLASH fast low-angle shot, FOV ﬁeld of view, FS fat suppression, GRE gradient-echo, IW intermediate-weighted, MEMS multi-echo,
multi-slice, NEX number of excitations, MPR multiplanar reformation, PD proton density, SAG sagittal, SE spin-echo, SNR signal-to-noise ra-
tio, SPGR spoiled gradient-recalled echo, T1W T1-weighted, T2W T2-weighted, TE echo time, TR repetition time, TSE turbo spin-echo, WE
water excitation.Backround
Osteoarthritis (OA) of the knee is a signiﬁcant contributor to
disability and loss of independence among middle age and
elderly persons and presents a clear and growing public
health need (http://www.cdc.gov/nchs/fastats/arthrits.htm).
Because of the chronic nature of OA and its variable clinical
outcomes, the use of clinical endpoints in studies of risk and
prognostic factors and in clinical trials that test interventions
to prevent or slow the progression of this disease requires
studying large numbers of patients for long periods of
time, often at great expense. Developing effective medical
treatments to prevent or to reduce progression of OA is
hampered by the lack of robust biomarkers of disease onset
and progression.*Address correspondence and reprint requests to: Charles
Peterfy, M.D., Ph.D., Synarc Inc., 575 Market Street, 17th Floor,
San Francisco, CA 94105, USA. Tel: 1-415-817-8900; Fax: 1-
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1433The osteoarthritis initiative (OAI) is a publiceprivate part-
nership jointly sponsored by the National Institutes of Health
(NIH), including the National Institute of Arthritis and Muscu-
loskeletal and Skin Diseases (NIAMS), National Institute on
Aging (NIA), National Institute of Dental and Craniofacial
Research (NIDCR), National Center for Complementary
and Alternative Medicine (NCCAM), Ofﬁce of Research on
Women’s Health (ORWH), National Institute of Biomedical
Imaging and Bioengineering (NIBIB), and National Center
on Minority Health and Health Disparities (NCMHD), and
the pharmaceutical industry. The OAI is focused on identify-
ing the most promising biomarkers of development and pro-
gression of symptomatic knee OA. A total of 4796 men and
women, aged 45e79 years, who either have or are at in-
creased risk of developing knee OA have been enrolled in
the study. Annual radiography and magnetic resonance im-
aging (MRI) of the knee and clinical assessments of dis-
ease activity are being performed in all participants over
a period of 4 years. Genetic and biochemical specimens
are also being collected annually from all participants.
Table I
Final OAI knee MRI protocol acquisition time (min)
Scan Right
knee
Left
knee
Total
1 Localizer (3-plane) 0.5 0.5 1.0
2 COR IW 2D TSE 3.4 3.4 6.8
3 SAG 3D DESS WE 10.6 10.6 21.2
4 COR MPR SAG 3D DESS WE 0.0 0.0 0.0
5 AXIAL MPR SAG 3D DESS WE 0.0 0.0 0.0
6 COR T1W 3D FLASH WE* 8.6 e 8.6
7 SAG IW 2D TSE FS 4.7 4.7 9.4
8 SAG 2D MESE* 10.6 e 10.6
Total 38.4 19.2 57.6
*Acquired on only right knee, unless right knee contains metal in
which case, acquired on only left knee.
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source for identifying, characterizing and validating a broad
range of imaging biomarkers for OA of the knee that could
be used to investigate basic research hypotheses as well as
to serve as outcomes in clinical trials of new therapies.
Accordingly, the goals for the OAI MRI study protocol are
to (1) provide imaging data on as many articular structures
and features believed to be relevant to knee OA as possi-
ble; (2) provide images that are able to support as broad
a range of existing and anticipated measurement methods
for each of these structures and features as possible; and
(3) balance scientiﬁc requirements for image quality and
consistency against the need to maintain high throughput
of the participants and the ability of the participants to toler-
ate the annual MRI examinations.
The report outlines the rationale used by the OAI Imaging
Working Group, which included scientists and clinicians
from academia and industry with expertise in MRI of OA
and cartilage (see Acknowledgements), to address these
design considerations and ultimately to arrive at the knee
MRI protocol used in the OAI. This report is not intendedTable I
Final OAI knee MRI protocol
Scan Localizer COR IW
2D TSE
SAG
DES
Plane 3-plane Coronal Sagi
FS No No WE
Matrix (phase) 128 307 307
Matrix (frequency) 256 384 384
No. of slices 21 35 160
FOV (mm) 200 140 140
Slice thickness/gap (mm/mm) 5/1 3/0 0.7/0
Flip angle (() 40 180 25
TE/TR (ms/ms) 5/10 29/3700 4.7/1
Bandwidth (Hz/pixel) 250 352 185
Chemical shift (pixels) 1.8 1.3 0
No. excitations averaged 1 1 1
ETL 1 7 1
Phase encode axis A/P, R/L R/L A/P
Distance factor (%) 50 0 0
Phase oversampling 0 20 0
Slice oversampling 0 0 10
Phase resolution 50 80 80
Phase partial Fourier (8/8¼ 1) 1 1 1
Readout partial Fourier (8/8¼ 1) 1 1 1
Slice partial Fourier (8/8¼ 1) 1 1 0.75
X-resolution (mm) 0.391 0.365 0.365
Y-resolution (mm) 0.781 0.456 0.456to serve as a review of the literature on existing or emerging
imaging biomarkers of knee OA using MRI technology. Sev-
eral excellent reviews have recently been published, and
readers are referred to these for broad overviews of the
ﬁeld1e5.
A key consideration in protocol development for the OAI
was to identify which knee OA features to target. Since
OA affects several articular structures, and is believed to
progress through multiple pathogenic pathways, the imag-
ing protocol had to support multi-feature, structural assess-
ment of the knee. The OAI Imaging Working Group
prioritized the following knee structures: articular cartilage,
osteophytes, bone marrow abnormality (BMA), bone attri-
tion and cysts, the osteochondral junction (bone surface
area), meniscal integrity, synovial tissue, joint effusion,
anterior cruciate ligament (ACL) and posterior cruciate liga-
ment (PCL), medial collateral ligament (MCL) and lateral
collateral ligament (LCL). Quantitative assessment of artic-
ular cartilage morphology (e.g., volume, thickness, cartilag-
inous/denuded surface area, etc.) was considered to be
particularly important. Many assessments of the selected
knee structures have been previously validated using MRI
at 1.5 T, and are used widely clinically and in research6e14.
The above priorities determined that anatomical cover-
age had to include at least the entire patellar, femoral and
tibial cartilages but ideally the entire synovial cavity. Other
decisions with respect to acquisition planes, spatial resolu-
tion, image contrast, and acquisition time are discussed
below, but the general principles underlying the tradeoffs
are outlined in a report from the Workshop on Imaging
Osteoarthritis of the Knee15, held on December 5e6,
2002 in Bethesda, MD by Outcome Measures in Rheuma-
tology Clinical Trials (OMERACT) and Osteoarthritis Re-
search Society International (OARSI).
Early in the planning stages of the OAI, the decision was
made to purchase dedicated, state-of-the-art MRI systems
for each of the four study sites (The Ohio State University,
Columbus, OH; University of Maryland, School of Medicine,I
acquisition parameters
3D
S WE
COR T1W
3D FLASH WE
SAG 2D
MESE
SAG IW
2D TSE FS
ttal Coronal Sagittal Sagittal
WE No FS
512 269 313
512 384 448
80 21 37
160 120 160
1.5/0 3/0.5 3/0
12 n/a 180
6.3 7.57/20 10, 20, 30, 40,
50, 60, 70/2700
30/3200
130 250 248
0 1.8 0
1 1 1
1 1 5
R/L A/P A/P
0 16 0
0 0 40
0 0 0
100 70 70
1 0.875 1
1 1 1
0.75 0.75 1
0.313 0.313 0.357
0.313 0.446 0.511
1435Osteoarthritis and Cartilage Vol. 16, No. 12Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; and
Memorial Hospital of Rhode Island, Pawtucket, RI) to mini-
mize acquisition variability and accommodate the large
number of subjects to be examined over the course of the
study. In 2003, when the OAI study was being designed
and implemented, 3 Tesla (T) MRI systems had recently
been introduced to the commercial market but were not
yet routinely available in clinical settings. MRI at 3 T offered
potential advantages over 1.5 T in terms of signal level that
could be traded for increased signal-to-noise (SNR), spatial
resolution or imaging speed. This advantage was felt to be
particularly useful for T2 relaxation time measurement of
cartilage2,10,16,17 and was believed to outweigh potential
disadvantages of high ﬁeld strength, such as increased sus-
ceptibility to metallic artifacts, increased fat-water chemical
shift, and different tissue relaxation times than those
observed at 1.5 T18,19. Inspite of the relative lack of clinical
and research experience at 3 T, it was understood that
1.5 T knee MRI protocols would not translate directly to
3 T without adjusting for the differences detailed above.
Other important considerations for the OAI included: use
of commercially available, food and drug administration
(FDA)-approved, pulse sequences and radiofrequencyFig. 1. Orientation of coronal acquisitions. Coronal 2D and 3D acquisitions
long axis of the femoral diaphysis on the sagittal localizer (A) and to a line
localizer (B). Depiction of both posterior femoral cortices (arrows) within
example of COR 3D F(RF) coils; minimizing redundancy among acquisitions in
the measurements that could be derived from them; the
need to position and image both knees within 75 min to pre-
vent subject discomfort and minimize the risk of dropout;
and minimizing individual sequence acquisition times to re-
duce the possibility of motion artifacts and associated im-
age degradation, especially for 3D acquisitions and 2D
multi-echo spin-echo (MESE) acquisitions.
The process of meeting these diverse goals with a single,
uniform protocol entailed selecting the image contrasts
most likely to satisfy the anticipated needs and making
careful tradeoffs in image spatial resolution and tissue con-
trasts. To facilitate this process, a pilot study was under-
taken in which selected candidate acquisition sequences,
based on contrast parameters at 1.5 T, were optimized for
use at 3 T. A small sample of knees was then scanned
with the most promising acquisitions and the resulting
images visually evaluated by musculoskeletal imaging ex-
perts afﬁliated with the OAI (see Acknowledgements) for
suitability in cartilage segmentation and semi-quantitative
assessments of relevant tissues. Details of this pilot study
and its results can found on the OAI website (http://
www.oai.ucsf.edu).are prescribed coronal to the joint, with the slice axis parallel to the
tangent to the posterior cortices of the femoral condyles on the axial
two slices (3 mm) of each other conﬁrms proper alignment on this
LASH WE (C).
Fig. 4. SAG 3D DESS WE. Note the clear delineation of the carti-
lage-cartilage (small arrows) and cartilage-capsule (large arrow)
interfaces as well as the interfaces between cartilage and adipose
(F), bone (B) and meniscus (M).
Fig. 2. Example of COR IW 2D TSE. Note delineation of the MCL,
LCL, body segments of the menisci, central tibial and femoral bone
margins and the central tibiofemoral articular cartilage. Note that
chemical-shift artifact is relatively mild.
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The ﬁnal OAI knee MRI protocol is shown in Tables I and
II. Subject positioning and scan set up can be found in detail
in the OAI MRI Operator’s Manual available on the website
(http://www.oai.ucsf.edu). The knee MRI acquisition begins
with a three-plane localizer, followed by a coronal interme-
diate-weighted (IW) 2D turbo spin-echo (TSE) (COR IW
2D TSE)7 for evaluating the MCL and LCL, marginal femo-
ral and tibial osteophytes, the medial and lateral meniscal
body segments, and the presence/extent of subchondral
bone cysts and bone attrition. All 2D and 3D coronal acqui-
sitions are oriented coronal to the joint based on anatomic
landmarks using a double oblique prescription (Figs. 1
and 2)9 in order to improve the reproducibility of cross-
sectional anatomy depicted on serially acquired MRI
exams.
The coronal plane1,9,15 is excellent for evaluating articular
cartilage along the central weight-bearing surfaces of theFig. 3. Orientation of the sagittal acquisitions. Anatomical coverage on sa
entire patella and as much of the suprapatellar bursa as possible (A) Sagit
and sagittal to the joint, with the slice axis parallel to the long axis of the
a line tangent to the posterior cortices of the fefemur and tibia, where the cartilage curves up the tibial
spines and the corresponding curves of the adjacent femo-
ral condyles near the notch. This plane is also excellent for
delineating the osteochondral junctions at the medial and
lateral margins of the femur and tibia. Intermediate weight-
ing7 is used in COR IW 2D TSE to balance the need for an
echo time (TE) short enough to detect non-displaced menis-
cal tears but still long enough to discriminate articular carti-
lage. Because of the high density and linear orientation of
collagen ﬁbers in the MCL and LCL, these structures
show very rapid T2 relaxation and therefore good delinea-
tion with intermediate-TE sequences.
Although the 3D dual-echo in steady state (DESS) image
contrast21 has not been as extensively evaluated for quan-
titative cartilage measurements as have fat-suppressed 3D
fast low-angle shot (FLASH) or 3D spoiled gradient-recalledgittal 2D and 3D acquisitions should include the tibial tubercle, the
tal acquisitions are prescribed orthogonal to the coronal acquisitions
femoral diaphysis on the coronal localizer (B) and perpendicular to
moral condyles on the axial localizer (C).
Fig. 5. Coronal MPR of SAG 3D DESS WE. Orientation is identical
to that described in Fig. 1. Note the excellent delineation of the
cartilageeﬂuid interface (arrow), and the high contrast between
cartilage and bone (B) and cartilage and meniscus (M).
1437Osteoarthritis and Cartilage Vol. 16, No. 12echo (SPGR) image contrast, 3D DESS with selective
water excitation (WE) appeared to show better cartilage
discrimination in pilot scans using volunteer subjects, and
therefore was included in the OAI MRI protocol. SagittalFig. 6. Axial MPR of SAG 3D DESS WE. Axial coverage includes
any superior or inferior patellar osteophytes and extends to the tib-
ial epiphysis. Note the good cartilageeﬂuid contrast revealing thin-
ning of articular cartilage over the lateral facet of the patella (large
arrow). Note also, that a small aliasing artifact (small arrow) is pres-
ent at the top of the image but does not obscure any anatomy of
interest.
Fig. 7. Sensitivity to subarticular BMA and cysts. SAG IW 2D TSE
FS (A) shows both bone cysts (small arrow) and surrounding BMA
(large arrow) in the femoral trochlea of this knee. However, both
GRE scans, SAG 3D DESS WE (B) and COR 3D FLASH WE
(C), of the same knee show only the cysts in this location.
Fig. 8. SAG 2D MESE. Multiple contrast acquisitions having progressively longer TEs can be combined to generate T2 maps of the articular
cartilage and adjacent tissues. These seven images illustrate how changing the TE affects the relative signal and relative contrast among the
different tissues in the knee.
1438 C. G. Peterfy et al.: Knee MRI protocol for the osteoarthritis initiative(SAG) 3D DESS WE was found not only to provide excel-
lent cartilage delineation for morphological measurements,
such as total joint cartilage thickness and volume, it also
delineates osteophytes along the anterior and posteriormargins of the femur and tibia and the superior and inferior
margins of the patella with high resolution, shows tears of
the anterior and posterior horns of the menisci, depicts
subarticular bone cysts and bone attrition, and assesses
Fig. 8. (continued)
1439Osteoarthritis and Cartilage Vol. 16, No. 12integrity of the ACL and PCL and the patellar and quadri-
ceps tendons1,15. In addition, the SAG 3D DESS acquisition
is faster than an equivalent 3D FLASH (or SPGR) acquisi-
tion; the resultant time savings can be potentially traded
for increased SNR or spatial resolution. All 2D and 3D sag-
ittal acquisitions are oriented sagittal to the joint based on
anatomic landmarks and are orthogonal to the coronal
acquisitions (Figs. 3 and 4).
The 3D DESS WE acquisition selected uses 0.7 mm thick
slices. Thinner slices could have been obtained, however,
the cost in increased scan time and subsequent loss of
SNR was considered to be excessive. The 3D FLASH WE
acquisition, in contrast, uses 1.5 mm slices, as was the cor-
onal slice thickness that was previously validated at
1.5 T3,11,12,22,23. Because the SAG 3DDESSWE acquisition
has thin slices, the resultant images can also be reformatted
(MPR) into the coronal and axial planes (Figs. 5 and 6) to dis-
play optimally the tibial and central weight-bearing surface of
the femoral cartilage, as well as the trochlear and patellar
cartilage, respectively1,3,6,11,13. The multiplanar reformation
(MPR) images can be of variable slice thickness; 1.5 mm
was chosen for the OAI to enable comparison with the previ-
ously validated coronal 3D FLASH images. Other MPR ori-
entations and slice thicknesses can be retrospectively
calculated from the sagittal images. However, the in-plane
spatial resolution of the MPR images is governed by the
size and orientation of the voxels in the original acquisition.
The SAG 3D DESS WE series utilizes near anisotropic vox-
els (0.7 mm slice thickness 0.37 mm 0.46 mm) to maxi-
mize in-plane sagittal spatial resolution in a reasonable
acquisition time (10.5 min). The resultant in-plane coronal
MPR spatial resolution is thus 0.7 mm 0.37 mm.
The COR T1-weighted (T1W) 3D FLASH WE acquisition
also provides high-resolution delineation of articular carti-
lage9, and as noted above has been extensively validated
at 1.5 T and shown to support accurate quantiﬁcation of
the volume and thickness of cartilage over the tibial
plateaus and the central surface of the femur3,11,12. Since
the OAI MRI protocol was designed and implemented, 3D
FLASH WE at 3 T has been cross-validated with 3D FLASH
WE at 1.5 T for quantitative analysis of cartilage
morphology23,24.
The OAI protocol also includes SAG IW 2D TSE fat
suppression (FS), which provides excellent assessment ofthe ACL and PCL, the anterior and posterior horns of the
menisci, anterior and posterior osteophytes, synovial effu-
sion and peri-articular cysts and bursae. This technique
also delineates articular cartilage; although, not as well as
the 3D acquisitions do. To obtain relatively high spatial res-
olution in a relatively short acquisition time, the ﬁeld of view
(FOV) was made smaller (16 cm) than desired (24 cm) for
complete coverage of the synovial cavity. The unique con-
tribution of the SAG IW 2D TSE FS acquisition to the proto-
col is its sensitivity to BMA and subchondral cysts1,25e27
(Fig. 7A). Gradient-echo (GRE) techniques, such as 3D
DESS (Fig. 7B) and 3D FLASH (Fig. 7C), even with robust
FS, are relatively insensitive to BMA (large arrow in
Fig. 7A). They are, however, sensitive for subchondral cysts
(thin arrow).
Finally, SAG 2D MESE is included in the protocol to allow
quantiﬁcation of cartilage T2 relaxation times as well as to
provide a range of non-fat-suppressed image contrasts
(proton density [PD], IW, T2-weighted [T2W]) (Fig. 8) to
improve assessment of many joint components, including
ligaments and tendons, and the cartilageebone interface.
T2 relaxation times are believed to relate to the integrity
of cartilage matrix, particularly collagen, and therefore to
be potentially useful for evaluating early degeneration2,10,16.
Based on the acquisition time constraints, the OAI Imag-
ing Working Group decided that it was not feasible to obtain
all acquisitions in the ﬁnal protocol on both knees. Accord-
ingly, two acquisitions were excluded from the left knee
examination (Table I) unless subjects had surgical hard-
ware in the right knee, in which case, the two sequences
would be performed on the knee without surgical hardware.
Subjects with unilateral knee arthroplasty would have no
MRI examinations of the operated knee.
COR T1W 3D FLASH WE was elected to be acquired on
only one knee because SAG 3D DESS WE was considered
to provide better contrast for delineating the interface
between articular cartilage and a range of degenerated and
normal tissues, as well as better contrast for evaluating
menisci, ligaments and synovial effusion. In pilot scans of vol-
unteer knees, the cartilageecapsule and cartilageecartilage
interfaces (Fig. 4) were often difﬁcult to discriminate with 3D
FLASH WE, but were well discriminated with 3D DESS
WE. Both 3D FLASHWE and 3D DESSWE were felt to pro-
vide excellent delineation of osteophytes, however, the most
important contribution of SAG3DDESSWE in this protocol is
high-resolution delineation of articular cartilage.
3D FLASH WE and 3D DESS WE have subsequently
been cross-validated at 3 T for cartilage volume quantiﬁca-
tion28e35. The absolute value performance and testeretest
precision of the direct SAG 3D DESS and the coronal
MPR DESS image series were found to be comparable to
that provided by coronal 3D FLASH in a cross-sectional
analysis. These results, and the history of use in knee OA
studies, support the decision to include COR T1W 3D
FLASH WE in the OAI MRI protocol. However, insufﬁcient
acquisition time was available to perform this technique in
both knees. Similarly, SAG 2D MESE was performed on
only one of the two knees to meet imaging time constraints.
Finally, the Imaging Working Group felt that axial MPR of
the high-resolution SAG 3D DESS WE would provide sufﬁ-
cient visualization of the patellofemoral joint in a plane
orthogonal to the cartilage plate, and therefore excluded
direct axial imaging of either knee.
Total imaging time for the ﬁnal OAI knee MRI protocol is
58 min (Table I), leaving 17 min for subject positioning, coil
placement and for scan prescription to stay within the total
examination time limit of 75 min for both knees.
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In summary, the OAI MRI protocol offers a balance be-
tween the scientiﬁc and practical considerations in assess-
ing the key articular structures and features believed to be
involved in the development and progression of OA in the
knee. While implementation of such a long and rigorous
MRI protocol may not be feasible in the clinic or in all clinical
trials, it is hoped that OAI will help guide the development of
more streamlined protocols applicable for use at either 3 T
or 1.5 T.
Several limitations of the protocol development process
should be noted. We were limited to the acquisition and
analysis methods which had been validated as of 2003.
Although other MRI biomarkers that relate to cartilage
matrix damage2,5,20,36,37 and subchondral trabecular ar-
chitecture and bone volume14 have been described, the
current OAI MRI protocol does not have sufﬁcient imaging
time to support those measurements and still satisﬁes its
primary scientiﬁc objectives. Given time constraints for
planning and startup of the OAI, the knee MRI protocol
was ﬁnalized and implemented without formally assessing
the performance characteristics of any biomarker mea-
surements, such as cartilage volume, semi-quantitative
assessments of articular lesions, etc. Since the OAI pro-
tocol was implemented, several studies of quantitative
cartilage morphology using images acquired with the
OAI protocol and addressing measurement precision, 3D
FLASH vs 3D DESS comparisons and sensitivity to
change have been published28e35,38,39. These perfor-
mance parameters will continue to be important topics
for investigation.
No external validation (compared to cadaver or ar-
throscopy) of cartilage measurements or assessments
has been done using the OAI MRI protocol or any other
acquisition protocol at 3 T. Key parameters (e.g., spatial
resolution) of the 3D FLASH acquisitions included in the
OAI protocol were identical to those previously validated
at 1.5 T for quantitative cartilage measurements
compared to cadaver knees12. Moreover, 3D FLASH
acquisitions acquired with the same resolution at 1.5 T
and 3 T gave identical precision for quantitative cartilage
measurements23. We have no reason to believe that
external validation results would differ between 3 T and
1.5 T acquisitions, but studies are needed to conﬁrm
this.
The OAI clinical data set as well as the radiographic and
MRI images are available through the study’s public web-
site (www.oai.ucsf.edu). It is hoped that the OAI MRI im-
ages will support not only the majority of analysis
methods and imaging biomarker measurements that are
currently available but many of those yet to be developed.
We urge users of the OAI public data to employ a system-
atic framework, such as the OMERACT ﬁlter40, to the de-
velopment and validation of imaging biomarkers of OA.
The availability of these images to the general community
of investigators should serve to accelerate research in OA
and thus our understanding of this enigmatic disease and
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